Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Breast Neoplasms 24Lung Neoplasms 21Triple Negative Breast Neoplasms 16Neoplasm Metastasis 16Pancreatic Neoplasms 15Neoplasms 15Colorectal Neoplasms 14Stomach Neoplasms 13Head and Neck Neoplasms 12Esophageal Neoplasms 12Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Small Cell Lung Carcinoma 9Rectal Neoplasms 8Ovarian Neoplasms 8Leukemia, Myeloid, Acute 8Recurrence 7Nasopharyngeal Carcinoma 7Glioblastoma 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Mouth Neoplasms 4Lymphoma 4Endometrial Neoplasms 4Colonic Neoplasms 4

Interventions

Etoposide 3Carboplatin 3atezolizumab 2Cisplatin 2tislelizumab 1obinutuzumab 1lutetium Lu 177 dotatate 1durvalumab 1ceralasertib 1Paclitaxel 1Injections 1EC regimen 1Drug Therapy 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × Drug Therapy × 1 year × Clear all
NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Shanghai Henlius Biotech

Phase 3 Active not recruiting
200 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡